Tilray, Inc. (TLRY) Reports Q2 Loss of $0.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Tilray, Inc. Reports Second Quarter 2018 Earnings
August 28, 2018 4:05 PM EDTRevenue rises 95.2% to US$9.7 million in second quarter and 75.2% to US$17.6 million in first half of 2018 Tilray medical cannabis products now available to patients in 11 countries on five continents Company has signed agreements to supply adult-use cannabis to consumers in seven Canadian provinces and territories Significant progress achieved in expanding Companys global production capacity
NANAIMO, British Columbia--(BUSINESS WIRE)-- Tilray,Inc., (Tilray or the Company) (NASDAQ: TLRY) a global pioneer in cannabis... More
